Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice
Tóm tắt
Chronic activation of Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway contributes to vascular inflammation and atherosclerosis by inducing expression of genes involved in cell proliferation, differentiation and migration. We aimed to investigate whether enforced expression of negative regulators, the suppressors of cytokine signaling (SOCS1 and SOCS3), inhibits harmful JAK/STAT-mediated responses and affects atherosclerosis in apolipoprotein E knockout mice. Adenovirus-mediated SOCS1 transgene expression impaired the onset and progression of atherosclerosis without impact on lipid profile, whereas SOCS3 was only effective on early atherosclerosis. Mechanistically, SOCS gene delivery, primarily SOCS1, attenuated STAT1 and STAT3 activation and reduced the expression of STAT-dependent genes (chemokine/chemokine receptors, adhesion molecules, pro-inflammatory cytokines and scavenger receptors) in aortic tissue. Furthermore, atherosclerotic plaques exhibit a more stable phenotype characterized by lower lipids, T cells and M1 macrophages and higher M2 macrophages and collagen. Atheroprotection was accompanied by a systemic alteration of T helper- and T regulatory-related genes and a reduced activation state of circulating monocytes. In vascular smooth muscle cells and macrophages, SOCS gene delivery inhibited cytokine-induced STAT activation, pro-inflammatory gene expression, cell migration and proliferation. In conclusion, targeting SOCS proteins, predominantly SOCS1, to suppress pathological mechanisms involved in atheroma plaque progression and destabilization could be an interesting anti-atherosclerotic strategy.
Tài liệu tham khảo
Agrawal S, Febbraio M, Podrez E, Cathcart MK, Stark GR, Chisolm GM (2007) Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation 115:2939–2947. doi:10.1161/CIRCULATIONAHA.107.696922
Ait-Oufella H, Taleb S, Mallat Z, Tedgui A (2011) Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31:969–979. doi:10.1161/ATVBAHA110.207415
Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120:172–185. doi:10.1016/j.pharmthera.2008.08.002
Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B (2011) Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ Res 108:985–995. doi:10.1161/CIRCRESAHA.110.233775
Daniel JM, Dutzmann J, Bielenberg W, Widmer-Teske R, Gunduz D, Hamm CW, Sedding DG (2012) Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 107:261. doi:10.1007/s00395-012-0261-9
Fang M, Dai H, Yu G, Gong F (2005) Gene delivery of SOCS3 protects mice from lethal endotoxic shock. Cell Mol Immunol 2:373–377
Gharavi NM, Alva JA, Mouillesseaux KP, Lai C, Yeh M, Yeung W, Johnson J, Szeto WL, Hong L, Fishbein M, Wei L, Pfeffer LM, Berliner JA (2007) Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 282:31460–31468. doi:10.1074/jbc.M704267200
Grothusen C, Schuett H, Hillmer A, Lumpe S, Grote K, Ballmaier M, Bleich A, Glage S, Tietge UJ, Luchtefeld M, Schieffer B (2012) Role of suppressor of cytokine signaling-1 in murine atherosclerosis. PLoS One 7:e51608. doi:10.1371/journal.pone.0051608
Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Oie E, Aukrust P (2008) Atherosclerotic plaque stability—what determines the fate of a plaque? Prog Cardiovasc Dis 51:183–194. doi:10.1016/j.pcad.2008.09.001
Hernandez-Vargas P, Lopez-Franco O, Sanjuan G, Ruperez M, Ortiz-Munoz G, Suzuki Y, Aguado-Roncero P, Perez-Tejerizo G, Blanco J, Egido J, Ruiz-Ortega M, Gomez-Guerrero C (2005) Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol 16:1673–1683. doi:10.1681/ASN.2004050374
Keul P, Lucke S, von Wnuck LK, Bode C, Graler M, Heusch G, Levkau B (2011) Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 108:314–323. doi:10.1161/CIRCRESAHA.110.235028
Kiu H, Nicholson SE (2012) Biology and significance of the JAK/STAT signalling pathways. Growth Factors 30:88–106. doi:10.3109/08977194.2012.660936
Kuchibhotla S, Vanegas D, Kennedy DJ, Guy E, Nimako G, Morton RE, Febbraio M (2008) Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res 78:185–196. doi:10.1093/cvr/cvm093
Liang X, He M, Chen T, Liu Y, Tian YL, Wu YL, Zhao Y, Shen Y, Yuan ZY (2013) Multiple roles of SOCS proteins: differential expression of SOCS1 and SOCS3 in atherosclerosis. Int J Mol Med 31:1066–1074. doi:10.3892/ijmm.2013.1323
Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–325. doi:10.1038/nature10146
Lim WS, Timmins JM, Seimon TA, Sadler A, Kolodgie FD, Virmani R, Tabas I (2008) Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation 117:940–951. doi:10.1161/CIRCULATIONAHA.107.711275
Mallavia B, Oguiza A, Lopez-Franco O, Recio C, Ortiz-Munoz G, Lazaro I, Lopez-Parra V, Egido J, Gomez-Guerrero C (2013) Gene deficiency in activating fcgamma receptors influences the macrophage phenotypic balance and reduces atherosclerosis in mice. PLoS One 8:e66754. doi:10.1371/journal.pone.0066754
Mallavia B, Recio C, Oguiza A, Ortiz-Munoz G, Lazaro I, Lopez-Parra V, Lopez-Franco O, Schindler S, Depping R, Egido J, Gomez-Guerrero C (2013) Peptide inhibitor of NF-kappaB translocation ameliorates experimental atherosclerosis. Am J Pathol 182:1910–1921. doi:10.1016/j.ajpath.2013.01.022
Marrero MB (2005) Introduction to JAK/STAT signaling and the vasculature. Vascul Pharmacol 43:307–309
Miklossy G, Hilliard TS, Turkson J (2013) Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 12:611–629. doi:10.1038/nrd4088
Ortiz-Munoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C, Sanz A, Blanco J, Mezzano S, Ortiz A, Egido J, Gomez-Guerrero C (2010) Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 21:763–772. doi:10.1681/ASN.2009060625
Ortiz-Munoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, Lopez-Franco O, Munoz-Garcia B, Fernandez-Vizarra P, Ortega L, Egido J, Gomez-Guerrero C (2009) Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 29:525–531. doi:10.1161/ATVBAHA.108.173781
Palmer DC, Restifo NP (2009) Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 30:592–602. doi:10.1016/j.it.2009.09.009
Qin L, Huang Q, Zhang H, Liu R, Tellides G, Min W, Yu L (2014) SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function. J Am Coll Cardiol 63:21–29. doi:10.1016/j.jacc.2013.08.694
Rastmanesh MM, Bluyssen HA, Joles JA, Boer P, Willekes N, Braam B (2008) Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. Eur J Pharmacol 593:99–104. doi:10.1016/j.ejphar.2008.07.013
Recio C, Oguiza A, Lazaro I, Mallavia B, Egido J, Gomez-Guerrero C (2014) Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice. Arterioscler Thromb Vasc Biol 34:1953–1960. doi:10.1161/ATVBAHA.114.304144
Sakurai H, Tashiro K, Kawabata K, Yamaguchi T, Sakurai F, Nakagawa S, Mizuguchi H (2008) Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses. J Immunol 180:4931–4938. doi:10.4049/jimmunol.180.7.4931
Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA (2011) STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 22:211–219. doi:10.1016/j.cytogfr.2011.06.003
Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117:195–205. doi:10.1172/JCI29950
Tajiri K, Imanaka-Yoshida K, Matsubara A, Tsujimura Y, Hiroe M, Naka T, Shimojo N, Sakai S, Aonuma K, Yasutomi Y (2012) Suppressor of cytokine signaling 1 DNA administration inhibits inflammatory and pathogenic responses in autoimmune myocarditis. J Immunol 189:2043–2053. doi:10.4049/jimmunol.1103610
Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van SJ, Yoshimura A, Tedgui A, Mallat Z (2009) Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 206:2067–2077. doi:10.1084/jem.20090545
Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A (2011) Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 31:980–985. doi:10.1161/ATVBAHA.110.207464
Tang J, Kozaki K, Farr AG, Martin PJ, Lindahl P, Betsholtz C, Raines EW (2005) The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. Am J Pathol 167:901–912. doi:10.1016/S0002-9440(10)62061-5
Trengove MC, Ward AC (2013) SOCS proteins in development and disease. Am J Clin Exp Immunol 2:1–29
Veenbergen S, Bennink MB, de Hooge AS, Arntz OJ, Smeets RL, van den Berg WB, van de Loo FA (2008) Splenic suppressor of cytokine signaling 3 transgene expression affects T cell responses and prevents development of collagen-induced arthritis. Arthritis Rheum 58:3742–3752. doi:10.1002/art.24072
Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410–1422. doi:10.1038/nm.2538
White GE, Cotterill A, Addley MR, Soilleux EJ, Greaves DR (2011) Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. J Mol Histol 42:137–151. doi:10.1007/s10735-011-9317-7
Xie JJ, Wang J, Tang TT, Chen J, Gao XL, Yuan J, Zhou ZH, Liao MY, Yao R, Yu X, Wang D, Cheng Y, Liao YH, Cheng X (2010) The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 49:185–193. doi:10.1016/j.cyto.2009.09.007